Occurrence and Severity of Chemotherapy-Induced Peripheral Neuropathy and Its Association with Comorbidities in Patients Receiving Cytotoxic Chemotherapy: A Prospective Observational Study
CIPN and Comorbidity Association
-
Mandeep Singh Juneja
Acharya and BM Reddy College of Pharmacy, Bengaluru -560107, India AND ESIC Model Hospital, Rajajinagar, Bengaluru – 560010 Karnataka, India
-
Nandhana Rajesh
Acharya and BM Reddy College of Pharmacy, Bengaluru -560107, India AND ESIC Model Hospital, Rajajinagar, Bengaluru – 560010 Karnataka, India
-
Armagan Shahid
Acharya and BM Reddy College of Pharmacy, Bengaluru -560107, India AND ESIC Model Hospital, Rajajinagar, Bengaluru – 560010 Karnataka, India
-
Dr. Shivashankar G
Department of Pharmacy Practice, Acharya and BM Reddy College of Pharmacy, Bengaluru -560107, India
-
Dr. Laigin Sebastian
Department of Pharmacy Practice, Acharya and BM Reddy College of Pharmacy, Bengaluru -560107, India
-
Dr. Shwetha S
Consultant Medical Oncologist, Department of Medical Oncology, ESIC Model hospital, Rajajinagar, Bengaluru – 560010 Karnataka, India
Keywords:
CIPN, CTCAE, FACT-GOG-Ntx, Charlson Comorbidity Index, ROC analysis, QOL, NeurotoxicityAbstract
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common and dose-limiting adverse effect of cytotoxic chemotherapy that can significantly impair quality of life (QoL), compromise functional status, and affect treatment adherence. Early recognition is essential to improve patient outcomes.
Objectives: To evaluate the occurrence and severity of CIPN using clinician-based NCI-CTCAE grading and patient-reported FACT/GOG-Ntx scores, and to identify associated risk factors, including co morbidity burden.
Methods: In this prospective observational study, 200 patients receiving cytotoxic chemotherapy were assessed for CIPN using NCI-CTCAE version 5.0, the FACT/GOG-Ntx questionnaire, and the Charlson Comorbidity Index.
Results: CIPN was observed in 124 (62.0%) patients. According to NCI-CTCAE grading, 73 (36.5%) patients had grade 1 neuropathy, 44 (22.0%) had grade 2 neuropathy, and 7 (3.5%) had grade 3 neuropathy. The prevalence increased with age, reaching 13 (81.3%) patients in the 74–83-year age group, and was higher among females. A cumulative effect of chemotherapy was observed with increasing treatment cycles. Platinum-based agents, taxanes, and proteasome inhibitors were most commonly associated with CIPN. Quality of life was adversely affected in 144 (72.0%) patients. CTCAE grading showed a significant association with FACT/GOG-Ntx scores (p < 0.001), although agreement between the assessment tools was low (κ = 0.025).
Conclusion: CIPN is a common and clinically relevant toxicity influenced by cumulative chemotherapy exposure, neurotoxic drug class, and increasing age. Combining clinician-based toxicity grading with patient-reported outcome measures may improve early detection, comprehensive assessment, and management of CIPN while supporting treatment continuation and improving quality of life.
Downloads
References
Zajączkowska R, Kocot-Kępska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci. 2019;20(6):1451. https://doi.org/10.3390/ijms20061451
Mattar M, Umutoni F, Hassan MA, Wamburu MW, Turner R, Patton JS, et al. Chemotherapy-induced peripheral neuropathy: A recent update on pathophysiology and treatment. Life (Basel). 2024;14(8):991. https://doi.org/10.3390/life14080991
Egashira N. Pathological mechanisms and preventive strategies of oxaliplatin-induced peripheral neuropathy. Front Pain Res (Lausanne). 2021;2:804260. https://doi.org/10.3389/fpain.2021.804260
Yang Y, Zhao B, Gao X, Sun J, Ye J, Li J, et al. Targeting strategies for oxaliplatin-induced peripheral neuropathy: Clinical syndrome, molecular basis, and drug development. J Exp Clin Cancer Res. 2021;40(1):331. https://doi.org/10.1186/s13046-021-02141-z
Wu S, Xiong T, Guo S, Zhu C, He J, Wang S. An up-to-date view of paclitaxel-induced peripheral neuropathy. J Cancer Res Ther. 2023;19(6):1501-1508. https://doi.org/10.4103/jcrt.jcrt_1982_22
Ocean AJ, Vahdat LT. Chemotherapy-induced peripheral neuropathy: Pathogenesis and emerging therapies. Support Care Cancer. 2004;12(9):619-625. https://doi.org/10.1007/s00520-004-0657-7
Haryani H, Fetzer SJ, Wu CL, Hsu YY. Chemotherapy-induced peripheral neuropathy assessment tools: A systematic review. Oncol Nurs Forum. 2017;44(3):E111-E123. https://doi.org/10.1188/17.ONF.E111-E123
Burgess J, Ferdousi M, Gosal D, Boon C, Matsumoto K, Marshall A, et al. Chemotherapy-induced peripheral neuropathy: Epidemiology, pathomechanisms and treatment. Oncol Ther. 2021;9(2):385-450. https://doi.org/10.1007/s40487-021-00168-y
Mezzanotte JN, Grimm M, Shinde NV, Nolan T, Worthen-Chaudhari L, Williams NO, et al. Updates in the treatment of chemotherapy-induced peripheral neuropathy. Curr Treat Options Oncol. 2022;23(1):29-42. https://doi.org/10.1007/s11864-021-00926-0
Wang C, Chen S, Jiang W. Treatment for chemotherapy-induced peripheral neuropathy: A systematic review of randomized control trials. Front Pharmacol. 2022;13:1080888. https://doi.org/10.3389/fphar.2022.1080888
Molinares D, Kurtevski S, Zhu Y. Chemotherapy-induced peripheral neuropathy: Diagnosis, agents, general clinical presentation, and treatments. Curr Oncol Rep. 2023;25(11):1227–35. Available from: https://doi.org/10.1007/s11912-023-01449-7
Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol. 2020;38(28):3325–48. Available from: https://doi.org/10.1200/JCO.20.01399
Preti K, Davis ME. Chemotherapy-induced peripheral neuropathy: Assessment and treatment strategies for advanced practice providers. Clin J Oncol Nurs. 2024;28(4):351–7. Available from: https://doi.org/10.1188/24.CJON.351-357
Batash R, Asna N, Ali SH, Charkovsky T, Asali M, Pelles S, et al. Management of chemotherapy-induced peripheral neuropathy (CIPN) in oncologic patients—A new promise? Preliminary results. Cancers (Basel). 2025;17(20):3321. Available from: https://doi.org/10.3390/cancers17203321
Sałat K. Chemotherapy-induced peripheral neuropathy—Part 2: Focus on the prevention of oxaliplatin-induced neurotoxicity. Pharmacol Rep. 2020;72(3):508–27. Available from: https://doi.org/10.1007/s43440-020-00106-1
Donovan HS, Campbell GB. Persistent chemotherapy-induced peripheral neuropathy: Are dose reductions and drug modifications our only options? Gynecol Oncol. 2018;149(3):433–4. Available from: https://doi.org/10.1016/j.ygyno.2018.05.003
Gießen-Jung C, von Baumgarten L. Peripheral neuropathy as a side effect of chemotherapy and targeted therapy. Dtsch Med Wochenschr. 2018;113(13):970–8. Available from: https://doi.org/10.1055/s-0043-120839
Saad M, Tafani C, Psimaras D, Ricard D. Chemotherapy-induced peripheral neuropathy in the adult. Curr Opin Oncol. 2014;26(6):634–41. Available from: https://doi.org/10.1097/CCO.0000000000000139
Wang RY, Lin XL, Xiang ST, Sun QH, Ding XH. Risk factors for oxaliplatin-induced peripheral neuropathy: A systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2022;26(11):4028–43. Available from: https://doi.org/10.26355/eurrev_202206_28973
Pulvers JN, Marx G. Factors associated with the development and severity of oxaliplatin-induced peripheral neuropathy: A systematic review. Asia Pac J Clin Oncol. 2017;13(6):345–55. Available from: https://doi.org/10.1111/ajco.12694
Lixian S, Xiaoqian Y, Luyan G, Lizhi Z, Rui D, Hongyue Y, et al. Risk factors of paclitaxel-induced peripheral neuropathy in patients with breast cancer: A prospective cohort study. Front Oncol. 2024;14:1327318. Available from: https://doi.org/10.3389/fonc.2024.1327318
Hiramoto S, Asano H, Miyamoto T, Takegami M, Kawabata A. Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: A retrospective study in Japan. PLoS One. 2021;16(12):e0261473. Available from: https://doi.org/10.1371/journal.pone.0261473
St Germain DC, O’Mara AM, Robinson JL, Torres AD, Minasian LM. Chemotherapy-induced peripheral neuropathy: Identifying research gaps and associated changes to clinical trial design. Cancer. 2020;126(20):4602–13. Available from: https://doi.org/10.1002/cncr.33108
Postma TJ, Heimans JJ. Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol. 2000;11(5):509–13. Available from: https://doi.org/10.1023/a:1008345613594
Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L. Chemotherapy-induced peripheral neuropathy and its association with quality of life: A systematic review. Support Care Cancer. 2014;22(8):2261–9. Available from: https://doi.org/10.1007/s00520-014-2255-7
Beijers A, Mols F, Dercksen W, Driessen C, Vreugdenhil G. Chemotherapy-induced peripheral neuropathy and impact on quality of life 6 months after treatment. J Community Support Oncol. 2014;12(11):401–6. Available from: https://doi.org/10.12788/jcso.0086
Scheel A, Beijers AJM, Mols F, Faber CG, Vreugdenhil G. Chemotherapy-induced peripheral neuropathy: Impact on quality of life. Ned Tijdschr Geneeskd. 2014;158:A7455 27. Scheel A, Beijers AJM, Mols F, Faber CG, Vreugdenhil G. Chemotherapy-induced peripheral neuropathy: Impact on quality of life. Ned Tijdschr Geneeskd. 2014;158:A7455. Available from: https://pubmed.ncbi.nlm.nih.gov/25270958/
Hung HW, Liu CY, Chen HF, Chang CC, Chen SC. Impact of chemotherapy-induced peripheral neuropathy on quality of life in advanced lung cancer patients receiving platinum-based chemotherapy. Int J Environ Res Public Health. 2021;18(11):5677. Available from: https://doi.org/10.3390/ijerph18115677
Matsuoka H, Nakamura K, Matsubara Y, Ida N, Saijo M, Ogawa C, et al. Influence of chemotherapy-induced peripheral neuropathy on quality of life of gynecologic cancer survivors. Int J Gynecol Cancer. 2018;28(7):1394–402. Available from: https://doi.org/10.1097/IGC.0000000000001320
Tofthagen C. Patient perceptions associated with chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs. 2010;14(3):E22–8. Available from: https://doi.org/10.1188/10.CJON.E22-E28
Hertz DL. Exploring pharmacogenetics of paclitaxel- and docetaxel-induced peripheral neuropathy by evaluating the direct pharmacogenetic-pharmacokinetic and pharmacokinetic-neuropathy relationships. Expert Opin Drug Metab Toxicol. 2021;17(2):227-239. https://doi.org/10.1080/17425255.2021.1856367
Trivedi MS, Unger JM, Henry NL, Darke AK, Hertz DL, Brannagan TH, et al. Risk prediction model for taxane-induced peripheral neuropathy in early-stage cancer. JAMA Netw Open. 2026;9(4):e264901. https://doi.org/10.1001/jamanetworkopen.2026.4901
Sánchez-Barroso L, Apellaniz-Ruiz M, Gutiérrez-Gutiérrez G, et al. Concomitant medications and risk of chemotherapy-induced peripheral neuropathy. The Oncologist. 2019;24(8):e784-e792. https://doi.org/10.1634/theoncologist.2018-0418
Published
How to Cite
Issue
Section
Copyright (c) 2026 Mandeep Singh Juneja, Nandhana Rajesh, Armagan Shahid, Dr. Shivashankar G, Dr. Laigin Sebastian, Dr. Shwetha S
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright Policy & Licensing terms | Tropical Journal of Pharmaceutical and Life Sciences
